We serve Chemical Name:1-benzyl-4-(dichloromethyl)-5-nitroimidazole CAS:434326-06-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-benzyl-4-(dichloromethyl)-5-nitroimidazole
CAS.NO:434326-06-4
Synonyms:1-benzyl-4-dichloromethyl-5-nitroimidazole
Molecular Formula:C11H9Cl2N3O2
Molecular Weight:286.11400
HS Code:2933290090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:63.64000
Exact Mass:285.00700
LogP:3.83900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-benzyl-4-dichloromethyl-5-nitroimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-benzyl-4-dichloromethyl-5-nitroimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-benzyl-4-dichloromethyl-5-nitroimidazole Use and application,1-benzyl-4-dichloromethyl-5-nitroimidazole technical grade,usp/ep/jp grade.
Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 1-benzyl-4-(dichloromethyl)-5-nitroimidazole manufacturer There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 1-benzyl-4-(dichloromethyl)-5-nitroimidazole supplier APIs are generally manufactured through a variety of processes that include. 1-benzyl-4-(dichloromethyl)-5-nitroimidazole vendor The Branchburg factory first came under FDA scrutiny in late 2019, when agency inspectors began to document numerous quality control problems. By March, 2020, the FDA had deemed the manufacturing issues as “Official Action Indicated,” its most serious category of violation. 1-benzyl-4-(dichloromethyl)-5-nitroimidazole factory We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.
